search
Wegovy
Trends
- 1Stopping GLP-1 drugs may raise heart attack and stroke risk●Stopping GLP-1 drugs may raise heart attack and stroke risk, study finds
A new study finds that people who stop taking GLP-1 weight-loss and diabetes drugs, such as Ozempic and Wegovy, may face an increased risk of heart attack and stroke. The findings suggest the cardiovascular benefits of these medications depend on continued use, raising questions about how patients should manage long-term treatment.
- 2One in six children on GLP-1 drugs develop deficiencies●Study: One in six children on GLP-1 drugs developed nutritional deficiencies
A new study reports that about one in six children taking GLP-1 medications, such as Ozempic and Wegovy, developed nutritional deficiencies while on the drugs. The findings raise concerns that appetite suppression and reduced intake may leave some children short on key nutrients, prompting calls for closer monitoring of children prescribed these increasingly used weight-loss medications.
- 3Weight-Loss Drugs Are Reshaping Sleep Medicine▼Weight-Loss Drugs Are Redrawing the Map of Sleep Medicine
GLP-1 weight-loss drugs such as Ozempic and Wegovy are being linked to changes in sleep health, with researchers examining how significant weight loss affects sleep apnoea and other sleep disorders. The trend is prompting sleep medicine specialists to rethink diagnosis rates, treatment demand and how therapies like CPAP may be used as more patients take these medications.
- 4Expert warns high-dose GLP-1 drugs may have wider effects▼Functional medicine expert warns high-dose GLP-1 drugs may disrupt more than food cravings
A functional medicine expert is cautioning that high doses of GLP-1 weight-loss and diabetes drugs may affect more than appetite, potentially disrupting other bodily processes beyond food cravings. The warning, reported by Fox News, adds to ongoing debate about the safety and long-term effects of medications such as Ozempic and Wegovy as their use continues to expand.
- 5Weight-loss jab maker's Vogue World sponsorship sparks concern▼‘It’s problematic’: concern as weight-loss jab maker sponsors Vogue World event
Novo Nordisk, the maker of weight-loss injection Wegovy, is sponsoring Vogue World, and the partnership is drawing criticism from commentators who call it problematic. Critics argue that having a pharmaceutical weight-loss brand fund a major fashion event risks glamorising slimming jabs and reinforcing harmful body-image pressures in an industry already criticised for promoting thinness.
- 6GLP-1 drugs, mental health and exercise in menopause examined▼GLP-1's and mental health; exercise and menopause
Public health coverage is drawing together two related topics: the possible mental health effects of GLP-1 weight-loss and diabetes drugs, and the role of exercise for women going through menopause. Listeners are weighing reported mood changes linked to GLP-1 medications against growing evidence that physical activity can ease menopause symptoms such as hot flashes, sleep problems and weight gain.